AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a more restrictive label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback